Suggested remit: To appraise the clinical and cost effectiveness of upadacitinib within its marketing authorisation for treating active psoriatic arthritis.
 
Status In progress
Process STA 2018
ID number 2690

Provisional Schedule

Committee meeting 17 June 2021
Expected publication 26 August 2021

Project Team

Project lead Gavin Kenny

Email enquiries

Consultees

Companies sponsors AbbVie (upadacitinib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Psoriasis and Psoriatic Arthritis Alliance
Professional groups Royal College of Physicians

Commentators

Comparator companies AbbVie (adalimumab) (confidentiality agreement not signed, not participating)
  Accord Healthcare (methotrexate) (confidentiality agreement not signed, not participating)
  Advanz Pharma (methotrexate) (confidentiality agreement not signed, not participating)
  Amgen (adalimumab) (confidentiality agreement not signed, not participating)
  Aspire (leflunomide) (confidentiality agreement not signed, not participating)
  Biogen (adalimumab, etanercept, infliximab) (confidentiality agreement not signed, not participating)
  Celgene (apremilast) (confidentiality agreement not signed, not participating)
  Cipla EU (methotrexate) (confidentiality agreement not signed, not participating)
  Eli Lilly and Company (ixekizumab) (confidentiality agreement not signed, not participating)
  Fresenius Kabi (adalimumab) (confidentiality agreement not signed, not participating)
  Hospira UK (methotrexate) (confidentiality agreement not signed, not participating)
  Intrapharm Laboratories (methotrexate) (confidentiality agreement not signed, not participating)
  Janssen-Cilag (gueslkumab, ustekinumab)
  Medac GmbH (leflunomide, methotrexate) (confidentiality agreement not signed, not participating)
  Merck, Sharp & Dohme (golimumab, infliximab) (confidentiality agreement not signed, not participating)
  Morningside Healthcare (methotrexate) (confidentiality agreement not signed, not participating)
  Mylan (adalimumab, leflunomide) (confidentiality agreement not signed, not participating)
  Napp Pharmaceuticals (infliximab) (confidentiality agreement not signed, not participating)
  Nordic Pharma (methotrexate) (confidentiality agreement not signed, not participating)
  Novartis (secukinumab) (confidentiality agreement not signed, not participating)
  Orion Pharma UK (methotrexate) (confidentiality agreement not signed, not participating)
  Pfizer (etanercept, infliximab, methotrexate, tofacitinib)
  Relonchem (leflunomide) (confidentiality agreement not signed, not participating)
  Rosemont Pharmaceuticals (methotrexate) (confidentiality agreement not signed, not participating)
  Samsung Bioepis (adalimumab, etanercept) (confidentiality agreement not signed, not participating)
  Sandoz (adalimumab, etanercept, infliximab, leflunomide, methotrexate) (confidentiality agreement not signed, not participating)
  Sanofi (leflunomide) (confidentiality agreement not signed, not participating)
  Therakind (methotrexate) (confidentiality agreement not signed, not participating)
  UCB Pharma (certolizumab pegol) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
07 October 2020 Invitation to participate
05 October 2020 In progress
12 June 2020 - 10 July 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance